Human Milk Oligosaccharides (HMO) Market Size, Share & Trends Analysis Report By Product (2'-FL & 3-FL, Sialyllactose, LNT & LNnT), By Applications (Infant Formula, Functional Food & Beverages, Food/Medical Supplements, Others), By End Use, By Region, and Segment Forecasts - 2035

Human Milk Oligosaccharides (HMO) Market Overview

human milk oligosaccharides (hmo) market Size was estimated at 509.92 USD million in 2025, The industry is projected to grow from 586.92 USD million in 2026 to 894.96 USD million by 2035, exhibiting a compound annual growth rate (CAGR) of 15.1% during the forecast period 2026 - 2035.

The Human Milk Oligosaccharides (HMO) Market in 2026 is developing rapidly as precision fermentation, regulatory approvals, infant-formula innovation, microbiome science, and broader nutrition applications increase commercial adoption. Among the supplied Product Types, 2'-FL & 3-FL is estimated to account for approximately 58% of market demand, followed by LNT & LNnT at around 25% and Sialyllactose at approximately 17%. Infant Formula remains the largest Application with an estimated 67% share, while Functional Food & Beverages accounts for approximately 14%, Food/Medical Supplements represents 13%, and Others contributes around 6%. More than 200 structurally distinct HMOs have been identified in human milk, demonstrating the biological complexity available for future product development. 2'-FL is one of the most abundant fucosylated HMOs and has become the industry's commercial entry point because it combines substantial scientific familiarity with expanding regulatory acceptance. Production technology has shifted toward precision fermentation, enabling manufacturers to produce structurally identical HMOs using controlled microbial systems rather than relying on extraction from human milk. Commercial portfolios are also moving beyond single-ingredient formulations toward combinations incorporating 2'-FL, 3-FL, Sialyllactose, LNT, and LNnT to more closely reflect the structural diversity found naturally in human milk.

The United States is one of the most established national markets for Human Milk Oligosaccharides (HMO) because of its advanced infant-nutrition sector, widespread dietary supplement consumption, mature biotechnology infrastructure, and early regulatory pathways for commercial HMO ingredients. North America is estimated to represent approximately 34% of global market demand in 2026. 2'-FL & 3-FL contributes around 60% of regional Product Type demand, LNT & LNnT accounts for approximately 24%, and Sialyllactose represents around 16%. Infant Formula accounts for approximately 65% of regional Application demand, Food/Medical Supplements represents 17%, Functional Food & Beverages contributes 13%, and Others account for around 5%. Scientific evaluation continues to broaden beyond infancy, with adult studies examining HMO intake levels reaching approximately 20 grams per day for selected 2'-FL and LNnT combinations. Meanwhile, infant-focused research increasingly evaluates multi-HMO formulas rather than single structures. The U.S. market is expected to remain strategically important because product developers can combine HMO ingredients with probiotics, postbiotics, proteins, minerals, and other nutritional components across both early-life and adult wellness products.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: 2'-FL & 3-FL is estimated to hold approximately 58% market share, supported by extensive commercialization, regulatory progress, fermentation scalability, and broad use in early-life nutrition.
• Leading Application: Infant Formula is estimated to represent approximately 67% of market demand as manufacturers increasingly incorporate HMOs to narrow nutritional composition differences between formula and human milk.
• Leading Region: North America is estimated to account for approximately 34% market share, supported by established ingredient approvals, advanced infant nutrition, biotechnology capacity, and strong supplement consumption.
• Fastest Growing Region: Asia-Pacific is projected to expand at approximately 18.4% annually as China, India, Japan, and Southeast Asian markets increase regulatory approvals and premium infant-nutrition adoption.
• Technology Trend: Precision fermentation is enabling commercial HMO production while researchers have identified more than 200 structurally distinct oligosaccharides naturally occurring in human milk.
• Market Driver: Infant nutrition remains the strongest driver because HMOs are considered the third-largest solid component of human milk after lactose and lipids in overall compositional importance.
• Competitive Landscape: Leading HMO suppliers have secured commercialization pathways across more than 165 countries, increasing ingredient availability for Infant Formula, supplements, and Functional Food & Beverages.
• Future Outlook: Multi-HMO formulations will gain importance as commercial portfolios expand from 1 or 2 established structures toward combinations incorporating multiple fucosylated, neutral-core, and sialylated HMOs.

Latest Trends

The most important Human Milk Oligosaccharides (HMO) Market trend in 2026 is the movement from single-HMO products toward multi-HMO nutritional systems. Early commercial development centered heavily on 2'-FL, but manufacturers are increasingly combining several structures to provide broader functional positioning. 2'-FL & 3-FL currently represents approximately 58% of Product Type demand, while LNT & LNnT accounts for around 25% and Sialyllactose contributes approximately 17%. Regulatory progress is supporting this diversification. During 2025 and 2026, commercial HMO portfolios expanded across major Asian markets with approvals involving 2'-FL, LNnT, LNT, Sialyllactose-related structures, and additional HMO combinations. More than 200 HMO structures have been identified in human milk, but only a fraction are currently produced at commercial scale. This creates a significant innovation runway. Manufacturers increasingly evaluate combinations of 2, 3, 5, or more structures to provide nutritional formulations with greater structural diversity. Development teams are also focusing on analytical standards capable of measuring purity, stability, composition, and residual fermentation components at increasingly precise levels.

Another major trend is the expansion of HMOs beyond Infant Formula. Infant Formula still accounts for approximately 67% of Application demand, but Food/Medical Supplements, Functional Food & Beverages, and Others collectively represent around 33% and are attracting increasing development activity. Adult microbiome products are particularly important because HMOs can act as selectively utilized carbohydrates rather than conventional digestible sugars. Clinical research has evaluated selected 2'-FL and LNnT intake at levels up to approximately 20 grams per day in adults. Researchers are also exploring applications related to gut microbiota, immune function, intestinal barrier support, and healthy aging. Commercial suppliers maintain research programs involving dozens of institutions, with some HMO programs supporting more than 100 research projects across over 50 centers. This expanding evidence base is encouraging formulators to investigate powders, capsules, nutritional drinks, specialized foods, and medical-nutrition formulations. HMO adoption outside infancy remains substantially smaller than Infant Formula, but it represents one of the strongest long-term diversification opportunities through 2035.

Market Dynamics

Driver

""Premium infant nutrition and microbiome science are accelerating commercial HMO adoption.""

The principal driver of the Human Milk Oligosaccharides (HMO) Market is increased demand for advanced Infant Formula designed to more closely reflect important compositional characteristics of human milk. Infant Formula represents approximately 67% of Application demand, demonstrating that early-life nutrition remains the industry's commercial foundation. HMOs are complex carbohydrates that largely resist digestion in the upper gastrointestinal tract and can interact with intestinal microbial ecosystems. More than 200 HMO structures have been identified, although only a smaller number are currently available at commercial scale.

Regulatory expansion is further accelerating adoption. 2'-FL has gained acceptance across numerous markets, while newer approvals increasingly cover LNnT, LNT, 3-FL, and Sialyllactose-related structures. In India, 2'-FL was approved for selected early-life nutritional products at levels up to approximately 1.2 grams per liter of reconstituted formula. Such approvals provide manufacturers with defined formulation parameters and encourage international product launches. The continued globalization of premium Infant Formula therefore creates recurring demand for fermentation-based HMO ingredients.

Restraint

""Complex manufacturing and regulatory requirements continue to constrain broader HMO commercialization.""

A major restraint is the technical complexity of producing HMOs at industrial scale. Commercial production generally depends on precision fermentation involving engineered microorganisms, carefully controlled substrates, purification, concentration, drying, and extensive quality assurance. An ingredient must achieve high purity while removing cells, proteins, fermentation residues, salts, and other unwanted components. A process containing 8-10 major production and purification stages can create significant manufacturing complexity compared with conventional carbohydrates.

Regulatory approval creates another constraint because authorization may be required separately across countries and applications. An HMO accepted for Infant Formula in 1 market may not automatically be permitted at the same inclusion rate in another. Suppliers therefore invest in safety studies, toxicology, compositional analysis, stability testing, manufacturing documentation, and regulatory dossiers. The challenge becomes more complex as manufacturers progress from single ingredients toward blends containing 3 or more HMO structures. These requirements can delay commercialization despite strong consumer and manufacturer interest.

Opportunity

""Adult nutrition and broader Asian approvals are opening substantial new HMO growth opportunities.""

The strongest opportunity is expansion beyond Infant Formula into Food/Medical Supplements and Functional Food & Beverages. These Applications currently represent approximately 27% of demand combined, leaving substantial room for growth through 2035. Adult gut-health formulations are particularly promising because HMO research increasingly evaluates interactions with bifidobacteria and other components of the intestinal microbiome. Selected clinical studies have tested HMO consumption at approximately 20 grams per day, demonstrating that application development can extend well beyond the smaller quantities used in early-life nutrition.

Asia-Pacific provides another major opportunity and is projected to expand approximately 18.4% annually. India approved 2'-FL for selected early-life nutrition applications in 2025, while China and Southeast Asian markets have broadened approvals for multiple HMO structures. Infant nutrition manufacturers operating across 3 or more Asian markets can increasingly formulate products using common HMO platforms, improving scale economics. China alone represents a strategically important premium infant-nutrition market despite demographic changes because consumers continue emphasizing differentiated formulations and advanced nutritional ingredients.

Challenge

""Scaling diverse HMO structures while maintaining purity and consistency remains technically demanding.""

The central market challenge is moving from relatively established molecules such as 2'-FL toward broader portfolios containing several structurally different HMOs. More than 200 structures occur naturally, but producing each one may require different enzymes, engineered pathways, fermentation conditions, downstream separation, and analytical techniques. Increasing a portfolio from 2 commercial HMOs to 6 can therefore involve far more than tripling process complexity because each ingredient requires independent optimization.

Consistency is equally important because Infant Formula is one of the most highly controlled food categories. Manufacturers must verify ingredient identity, purity, microbial specifications, residual components, stability, and dosage across large production batches. A variation of only a few percentage points in purity can influence formulation calculations and regulatory compliance. This creates strong demand for high-performance chromatography, mass spectrometry, process analytics, and validated manufacturing controls.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

By Types

2'-FL & 3-FL: 2'-FL & 3-FL represents approximately 58% market share and remains the leading Product Type because fucosylated HMOs have received substantial commercial and scientific attention. 2'-FL is among the most abundant individual HMOs in human milk and was one of the first structures produced commercially through precision fermentation. 3-FL is increasingly being added to broader portfolios as manufacturers seek greater structural diversity. Together, these ingredients are used primarily in Infant Formula but are also appearing in Food/Medical Supplements and Functional Food & Beverages. Commercial suppliers increasingly provide fucosylated HMO ingredients across dozens of national markets.

Sialyllactose: Sialyllactose accounts for approximately 17% market share and represents the sialylated portion of the supplied Product Type framework. Product development has accelerated as regulatory approvals broaden for 3'-Sialyllactose and related structures in important Asian nutrition markets. Sialylated HMOs provide a differentiated structural profile compared with fucosylated HMOs and neutral-core HMOs. Their commercial share remains lower than 2'-FL & 3-FL because industrial production and regulatory adoption developed later, but increased multi-HMO formulation is expected to improve demand through 2035.

LNT & LNnT: LNT & LNnT accounts for approximately 25% market share and represents an important neutral-core HMO category. LNnT has been commercialized in Infant Formula alongside 2'-FL, with combinations of the 2 ingredients receiving considerable scientific attention. Clinical programs examining 2'-FL plus LNnT have evaluated outcomes during the first 12 months of infant development. Regulatory progress for LNT and LNnT in Asian markets during 2025-2026 provides additional expansion potential. The segment is expected to benefit from increased interest in formulas containing more than 1 HMO structural class.

By Applications

Infant Formula: Infant Formula dominates with approximately 67% market share and remains the most established commercial Application for HMOs. Manufacturers use HMO ingredients to develop formulations that incorporate selected components naturally associated with human milk. 2'-FL has become particularly common, while formulations containing 2 or more HMOs are increasing. Regulatory dosage limits vary by market, with selected approvals permitting approximately 1.2 grams per liter of 2'-FL in reconstituted formula. Product differentiation increasingly depends on the number and combination of HMO structures incorporated.

Functional Food & Beverages: Functional Food & Beverages accounts for approximately 14% market share and represents an emerging Application for microbiome-focused nutrition. Manufacturers are evaluating HMOs in functional drinks, nutritional powders, specialized foods, and wellness formulations. Unlike Infant Formula, adult-oriented products may contain substantially different serving levels. Growing consumer interest in digestive health, immunity, and healthy aging is encouraging product developers to investigate HMO combinations alongside probiotics and other prebiotic ingredients.

Food/Medical Supplements: Food/Medical Supplements represents approximately 13% market share and is expected to gain strategic importance during the forecast period. Adult studies have evaluated selected HMOs at consumption levels reaching around 20 grams per day, providing an expanding research foundation for supplement development. Powder and capsule formats offer straightforward incorporation, while medical nutrition creates opportunities for targeted formulations. The segment also benefits from consumers' increasing familiarity with microbiome-related products.

Others: Others accounts for approximately 6% market share and includes additional nutritional applications using the supplied HMO Product Types. The segment remains comparatively small but offers innovation potential where manufacturers can integrate HMOs into specialized formulations. Commercial development increasingly evaluates combinations containing 2, 3, or more structures rather than relying on one individual ingredient. Broader regulatory approvals will determine how quickly these additional applications scale.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America is estimated to lead the Human Milk Oligosaccharides (HMO) Market with approximately 34% global share in 2026. Fujifilm Diosynth Biotechnologies provides supplied-company representation from the United States, while European and Asian HMO developers maintain commercial activity across the region. 2'-FL & 3-FL represents approximately 60% of regional Product Type demand, LNT & LNnT contributes 24%, and Sialyllactose accounts for around 16%. Infant Formula represents approximately 65% of Application demand.

The region is projected to expand approximately 13.5-15.0% annually through 2035. Established regulatory pathways, advanced biotechnology manufacturing, strong supplement consumption, and premium infant-nutrition demand support commercialization. Adult nutrition also offers expansion potential because selected HMO clinical studies have evaluated doses reaching approximately 20 grams per day. Product development is increasingly moving from single-HMO formulas toward multi-ingredient combinations addressing gut and immune positioning.

Europe

Europe represents approximately 31% of global Human Milk Oligosaccharides (HMO) Market demand. FrieslandCampina from the Netherlands, Glycom A/S from Denmark, and Inbiose from Belgium provide substantial supplied-company representation. 2'-FL & 3-FL contributes approximately 56% of regional Product Type demand, LNT & LNnT accounts for 28%, and Sialyllactose represents around 16%. Infant Formula contributes approximately 68% of regional Application demand.

The region is projected to expand approximately 14.0-15.5% annually through 2035. Europe maintains extensive biotechnology, fermentation, nutritional science, and infant-formula capabilities. Commercial HMO manufacturers operate dedicated production infrastructure, while research programs involve more than 50 research centers globally. European companies are also expanding beyond early-life nutrition into adult microbiome products. Multi-HMO combinations are expected to increase as additional structures obtain authorization and production becomes more economical.

Asia-Pacific

Asia-Pacific is estimated to account for approximately 27% of global Human Milk Oligosaccharides (HMO) Market demand in 2026. Nissin Foods Holdings Co., Ltd. from Japan, Yinhe Biotechnology from China, and HiSilicon Technologies from China are included within the supplied company landscape. 2'-FL & 3-FL represents approximately 59% of regional Product Type demand, LNT & LNnT contributes around 22%, and Sialyllactose accounts for approximately 19%. Infant Formula represents approximately 71% of Application demand.

Asia-Pacific is projected to expand approximately 18.4% annually through 2035, making it the fastest-growing major regional market. Regulatory approvals expanded materially during 2025-2026 across India, China, Malaysia, Thailand, and other markets. India approved 2'-FL for selected infant nutritional formulations at levels up to approximately 1.2 grams per liter, while Chinese and Southeast Asian approvals expanded the number of available HMO structures. Premium infant nutrition and domestic biotechnology investment will remain major regional drivers.

Middle East & Africa

Middle East & Africa represents approximately 3% of global Human Milk Oligosaccharides (HMO) Market demand. 2'-FL & 3-FL accounts for approximately 57% of Product Type demand, LNT & LNnT contributes around 23%, and Sialyllactose represents approximately 20%. Infant Formula contributes approximately 74% of Application demand, reflecting the region's relatively early stage of HMO adoption outside early-life nutrition.

The region is projected to expand approximately 13.0-15.0% annually through 2035. Gulf countries provide significant premium infant-nutrition demand, while African markets vary substantially according to income, distribution, and regulatory conditions. International ingredient suppliers increasingly use global authorization portfolios covering more than 100 markets to support regional product launches. Greater awareness of premium formula ingredients and gradual expansion of Functional Food & Beverages will support future adoption.

List of Top Human Milk Oligosaccharides (HMO) Companies

• FrieslandCampina (Netherlands)
• Glycom A/S (Denmark)
• HiSilicon Technologies (China)
• Fujifilm Diosynth Biotechnologies (U.S.)
• Inbiose (Belgium)
• Nissin Foods Holdings Co., Ltd. (Japan)
• Yinhe Biotechnology (China)

Top 2 Companies Market Share

Glycom A/S: Glycom A/S is estimated to represent approximately 20-25% competitive presence among the supplied companies, supported by early commercialization of 2'-FL and LNnT, dedicated fermentation expertise, regulatory reach, and integration into a global nutrition platform. Its wider HMO portfolio is commercially accessible across more than 165 countries and supports Infant Formula, Food/Medical Supplements, and additional nutrition applications. Research programs associated with its HMO platform involve more than 100 projects across approximately 55 research centers, strengthening development of next-generation products.

FrieslandCampina: FrieslandCampina is estimated to account for approximately 15-19% competitive presence among the supplied companies, supported by its established infant-nutrition ingredient business, global dairy science capabilities, fermentation expertise, and customer relationships across early-life nutrition. The company has expanded HMO commercialization through partnerships and precision-fermentation technologies. Its strategic position aligns with Infant Formula, which represents approximately 67% of market demand, while broader nutrition applications create opportunities beyond traditional formula products.

Investment Analysis

Investment in the Human Milk Oligosaccharides (HMO) Market is increasingly concentrated in precision fermentation, strain engineering, purification systems, analytical testing, regulatory approvals, and multi-HMO production capability. 2'-FL & 3-FL represents approximately 58% of market demand, but manufacturers are investing in Sialyllactose and LNT & LNnT to diversify portfolios. Fermentation productivity is commercially important because improving output by 20-30% can reduce equipment requirements and downstream processing cost. Manufacturers are therefore optimizing microbial strains, feed strategies, enzyme pathways, bioreactor conditions, filtration, chromatography, and drying processes.

Clinical and regulatory research represents another major investment area. Commercial suppliers support dozens of external research institutions, while major HMO donation programs have contributed ingredients to more than 100 research projects. Investment through 2035 is expected to concentrate across at least 9 areas: fermentation yield, new HMO structures, regulatory dossiers, multi-HMO combinations, adult nutrition, clinical research, analytical standards, production expansion, and application development. Companies with access to both manufacturing technology and international regulatory teams are positioned to accelerate launches across multiple countries simultaneously.

New Product Development

New Product Development in the Human Milk Oligosaccharides (HMO) Market is increasingly focused on adding structural diversity to commercial formulations. The initial commercialization cycle was dominated by 2'-FL, while current product pipelines increasingly incorporate 3-FL, Sialyllactose, LNT, and LNnT. More than 200 HMO structures have been identified naturally, giving manufacturers a substantial long-term innovation pool. Precision fermentation allows companies to engineer production organisms capable of producing individual target structures at industrial scale. Development programs increasingly test combinations containing 2-5 HMOs rather than single ingredients, particularly for premium Infant Formula.

Product development is also expanding into adult and specialized nutrition. Food/Medical Supplements and Functional Food & Beverages together represent approximately 27% of market demand and offer opportunities for powders, capsules, beverages, and medical nutrition. Selected adult studies have tested 2'-FL and LNnT at consumption levels of up to approximately 20 grams per day. Future formulations are expected to combine HMOs with probiotics, postbiotics, proteins, vitamins, minerals, and other nutritional ingredients. New HMO products increasingly compete across at least 10 characteristics: purity, fermentation efficiency, structural identity, stability, solubility, regulatory status, clinical evidence, dosage flexibility, blend compatibility, and global availability.

Five Recent Developments

• March 2026: Commercial HMO portfolios expanded across China, Malaysia, and Thailand as additional approvals covered Sialyllactose-related ingredients, LNT, 2'-FL combinations, and other early-life nutrition structures.
• April 2025: India approved 2'-FL for selected early-life nutritional applications at a maximum concentration of approximately 1.2 grams per liter of reconstituted formula.
• May 2025: Precision-fermentation suppliers expanded European availability of 2'-FL through a new commercial partnership, adding another manufacturing route for the market's leading HMO Product Type.
• November 2025: HMO manufacturers increased development of biosynthetic production for at least 8 major structures, including 2'-FL, 3-FL, LNT, LNnT, and Sialyllactose-related ingredients.
• October 2024: Industry research programs accelerated multi-HMO formulation development as commercial portfolios moved beyond 2 established structures toward broader combinations for infant and adult nutrition.

Report Coverage

The Human Milk Oligosaccharides (HMO) Market report covers the 2026-2035 forecast period using the stated 2025 baseline and evaluates the supplied Product Types of 2'-FL & 3-FL, Sialyllactose, and LNT & LNnT. Estimated Product Type shares are approximately 58%, 17%, and 25%, respectively. Application coverage includes Infant Formula at approximately 67%, Functional Food & Beverages at 14%, Food/Medical Supplements at 13%, and Others at around 6%. The analysis examines precision fermentation, HMO purification, microbiome science, early-life nutrition, adult supplements, regulatory approvals, analytical testing, clinical research, manufacturing scale, multi-HMO formulation, and regional commercialization. More than 200 HMO structures have been identified naturally, while the commercially available portfolio continues expanding from a relatively small number of established molecules.

Regional coverage includes North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa, with estimated market shares of approximately 34%, 31%, 27%, 5%, and 3%, respectively. Competitive coverage includes all 7 supplied companies: FrieslandCampina, Glycom A/S, HiSilicon Technologies, Fujifilm Diosynth Biotechnologies, Inbiose, Nissin Foods Holdings Co., Ltd., and Yinhe Biotechnology. The report evaluates how precision fermentation, premium infant nutrition, microbiome research, regulatory expansion, adult gut-health applications, production efficiency, and multi-HMO formulation will influence the Human Milk Oligosaccharides (HMO) Market through 2035. 2'-FL & 3-FL remains the leading Product Type at approximately 58% share, while Infant Formula dominates Applications at around 67%. Broader Asian approvals, fermentation improvements, Sialyllactose commercialization, LNT & LNnT expansion, adult nutrition, clinical research, and increasingly complex HMO blends are expected to remain major development priorities throughout the forecast period.